Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1325-1330

  Shin, Dong M ^a   Glisson, Bonnie S ^a   Khuri, Fadlo R ^a   Ginsberg, Lawrence ^a   Papadimitrakopoulou, Vali ^a   Lee, J Jack ^a   Lawhorn, Kristie ^a   Gillenwater, Ann M ^a   Ang, Kie Kian ^a   Clayman, Gary L ^a   Callender, David L ^a   Hong, Waun Ki ^a   Lippman, Scott M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; IFOSFAMIDE; MESNA; PACLITAXEL;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; VOMITING;

EID: 0031897977     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1325     Document Type: Article

References (19)

1. Landis SH, Murray T, Bolden S, et al: Cancer Statistics 1998. CA Cancer J Clin 48:6-29, 1998
2. Clayman GL, Lippman SM, Laramore G, et al: Head and neck cancer, in Holland JF, Frei E, Bast RC, Jr, Kufe DW, Morton DL, Weichselbaum RR (eds): Cancer Medicine (ed 4). Baltimore, MD, Williams & Wilkins 1997, pp 1645-1710
3. Schantz SP, Harrison LB, Forastiere AA: Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 741-801
4. Lippman SM, Hong WK: Chemotherapy and chemoprevention, in Myers EN, Suen JY (eds): Cancer of the Head and Neck (ed 3). Philadelphia, PA, Saunders, 1996, pp 782-804
5. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993
6. Forastiere AA, Shank D, Neuberg D, et al: Final report of a phase II evaluation of paclitaxel in advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group trial (PA390). Cancer (in press)
7. Huber MH, Lippman SM, Benner SE, et al: A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. Am J Clin Oncol 19:379-382, 1996
8. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247-1259, 1990
9. Benner SE, Lippman SM, Huber MH, et al: Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck. Semin Oncol 22:22-25, 1995
10. Miller AB, Hoogstraten B, Staquet M: Reporting results of cancer treatment. Cancer 47:207-214, 1981
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
12. Paredes J, Hong WK, Felder RB, et al: Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 6:955-962, 1988
13. Dimery I, Martin T, Bradley E, et al: Phase I trial of interleukin-2 plus cisplatin and 5-fluorouracil in recurrent or advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 8:170, 1989 (Abstr)
14. Huber MH, Shirinian M, Lippman SM, et al: Phase I/II study of cisplatin, 5-fluorouracil and α-interferon for recurrent carcinoma of the head and neck. Invest New Drugs 12:223-229, 1994
15. Papadimitrakopoulou VA, Dimery IW, Lee JJ, et al: Cisplatin, fluorouracil, and l-leucovorin induction chemotherapy for locally advanced head and neck cancer: The M.D. Anderson Cancer Center experience. Cancer J Sci Am 3:92-99, 1997
16. Vokes EE, Haraf DJ, Stenson K, et al: The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol 22:8-12, 1995
17. Forastiere AA, Leong T, Murphy B, et al: A phase III trial of high-dose paclitaxel plus cisplatin plus G-CSF versus low-dose paclitaxel plus cisplatin in patients with advanced squamous cell carcinoma of the head and neck (HNSCC): An Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol 16:384A, 1997 (abstr)
18. Rowinsky EK, Chaudhry V, Forastiere AA, et al: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11:2010-2020, 1993
19. Creaven P, Raghaven D, Pendyala L, et al: Phase I study of paclitaxel and carboplatin: Implication for trials in head and neck cancer. Semin Oncol 22:13-16, 1995